Sept. 28, 2023 — Maryland-based biotech company Deka Biosciences (“Deka”) today announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by …
Trending at Lumira Ventures
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, …
Molly Shoichet Joins PRIME as New Scientific Director for Precision Medicine Initiative
AmacaThera Co-Founder, Chief Scientific Officer and University Professor Molly Shoichet is the new Scientific Director of PRiME Next-Generation Precision Medicine, a University of Toronto (U of T) Strategic Initiative based at the Leslie Dan Faculty of Pharmacy. As an accelerator for precision …
Fall 2023 Lumira Venture Innovation Program (VIP): Venture Fellow Applications Open
Looking to make a career in life sciences innovation? Our Venture Innovation Program (VIP) is accepting applications for exceptional students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are committed to pushing the …
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
Montreal, Quebec – August 15, 2023 – Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced today FDA clearance of its Investigational New Drug application (IND) …
A 5-Year, $50k Pledge: Supporting Mélanie’s Way on Their Mission to Impact the Lives of Women with Metastatic Cancer and Their Families
Mélanie’s Way is a Canadian charity dedicated to granting personalized ‘wishes’ to send women battling cancer and their families on trips of a lifetime. The mission was inspired by Mélanie Chalmers who refused to be defined by the cancer that …
DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer
TORONTO, June 13, 2023 — DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the …
Managing General Partner, Peter van der Velden Wins the 2023 Barry Gekiere Lifetime Legacy Award
Throughout his more-than-30-year career, Peter van der Velden’s focus has not only been on investing, but also on making a lasting impact in healthcare. Although he initially contemplated becoming a doctor, he soon realized that he was more interested in the business …
Cadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation Therapy
Cadence Neuroscience announced that it has secured $26 million in Series B financing. The round was led by Angelini Lumira Biosciences Fund (co-managed by Lumira Ventures and Angelini Ventures) and included other new investors F-Prime Capital, LivaNova USA, Angelini Ventures, Spectrum Financial Services, …
Endotronix Extends Positive Outcomes with 12-month Data Release from the SIRONA 2 Trial for Remote Heart Failure Management Using the Cordella Pulmonary Artery Sensor
The study met secondary study endpoints and long-term sensor use was associated with significant improvements in patient quality-of-life metrics and low event rates for heart failure hospitalization and death. Endotronix, Inc., a digital health and medical technology company dedicated to advancing …
PIC Therapeutics Presents Pre-Clinical Data Update on eIF4E Regulators at AACR Annual Meeting 2023
PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric small molecule therapies targeting eIF4E, is presenting pre-clinical data today on the company’s advancing eIF4E program for breast cancer in a poster at the American …
Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO
Proceeds to Support Key Efficacy Studies for ABI-2280 including Phase 2 Trial in High-Grade Cervical Intraepithelial Neoplasia (CIN 2,3) and Exploratory Study as Treatment for High-Risk HPV Infections Antiva Biosciences, Inc. biopharmaceutical company developing novel, topical therapeutics for the treatment of …
Fusion Pharmaceuticals Announces IND Clearance For FPI-2068, A Jointly Developed Novel Targeted Alpha Therapy
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the clearance of investigational new drug (IND) applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue [111In]-FPI-2107 (FPI-2107) to the U.S. Food …
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets
Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced it has entered into a Research Collaboration and License agreement with Incyte to …
Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)
Deka Biosciences (“Deka”), a clinical-stage biotechnology company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced today that the first subject has been dosed in a Phase 1 clinical trial of DK210 (EGFR) at NEXT Oncology in Fairfax, …